Cargando…

Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan

miR profile could be associated to CV risk, and also to prognosis/outcome in response to therapeutic approach. We aimed to evaluate if anti-hypertensive drugs enalapril, losartan or olmesartan have effects on monocyte miR profile in essential hypertensives without target organ involvement. For this...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandraffino, Giuseppe, Lo Gullo, Alberto, Cinquegrani, Maria, D’Ascola, Angela, Sinicropi, Davide, Imbalzano, Egidio, Blando, Giuseppe, Campo, Giuseppe Maurizio, Morace, Carmela, Giuffrida, Clemente, Campo, Salvatore, Squadrito, Giovanni, Scuruchi, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389596/
https://www.ncbi.nlm.nih.gov/pubmed/34440064
http://dx.doi.org/10.3390/biomedicines9080860
_version_ 1783742895250997248
author Mandraffino, Giuseppe
Lo Gullo, Alberto
Cinquegrani, Maria
D’Ascola, Angela
Sinicropi, Davide
Imbalzano, Egidio
Blando, Giuseppe
Campo, Giuseppe Maurizio
Morace, Carmela
Giuffrida, Clemente
Campo, Salvatore
Squadrito, Giovanni
Scuruchi, Michele
author_facet Mandraffino, Giuseppe
Lo Gullo, Alberto
Cinquegrani, Maria
D’Ascola, Angela
Sinicropi, Davide
Imbalzano, Egidio
Blando, Giuseppe
Campo, Giuseppe Maurizio
Morace, Carmela
Giuffrida, Clemente
Campo, Salvatore
Squadrito, Giovanni
Scuruchi, Michele
author_sort Mandraffino, Giuseppe
collection PubMed
description miR profile could be associated to CV risk, and also to prognosis/outcome in response to therapeutic approach. We aimed to evaluate if anti-hypertensive drugs enalapril, losartan or olmesartan have effects on monocyte miR profile in essential hypertensives without target organ involvement. For this purpose, 82 hypertensives and 49 controls were included; we evaluated SBP/DBP, lipid profile, glucose, CRP, fibrinogen, arterial stiffness indices (PWV; AIx), and cIMT at baseline (T0) and after 24 weeks of treatment (T1). Subjects with LDL-C ≥ 160 mg/dL, TG ≥ 200 mg/dL, BMI ≥ 30, and other additional CV risk factors were excluded. Patients who were prescribed to receive once-a-day enalapril 20 mg, losartan 100 mg or olmesartan 20 mg were eligible for the study. At T1, we found a significant improvement of SBP (−18.5%), DBP (−18%), HDL-C and LDL-C (+3% and −5.42%), glucose (−2.15%), BMI (−3.23%), fibrinogen (−11%), CRP (−17.5%,), AIx (−49.1%) PWV (−32.2%), and monocyte miR expression (miR-221: −28.4%; miR-222: −36%; miR-145: +41.7%) with respect to baseline. miR profile was compared to control subjects at baseline and at T1. We found some little difference in the behaviour of the three treatments on some variables: olmesartan was the most effective in reducing fibrinogen, DBP, CRP, and AIx (−13.1%, −19.3%, −21.4%, and −56.8%, respectively). Enalapril was the drug more significantly increasing the expression of miR-145. In conclusion, enalapril, losartan and olmesartan are effective in improving mechanical and humoral factors associated to AS and atherogenesis. These drugs appear to be able to modify miRs 221/222 and miR-145 expression in drug-naïve hypertensives, making it closer to that of control subjects; additionally, this provides a good blood pressure compensation, contributing to slow the progression of vascular damage.
format Online
Article
Text
id pubmed-8389596
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83895962021-08-27 Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan Mandraffino, Giuseppe Lo Gullo, Alberto Cinquegrani, Maria D’Ascola, Angela Sinicropi, Davide Imbalzano, Egidio Blando, Giuseppe Campo, Giuseppe Maurizio Morace, Carmela Giuffrida, Clemente Campo, Salvatore Squadrito, Giovanni Scuruchi, Michele Biomedicines Article miR profile could be associated to CV risk, and also to prognosis/outcome in response to therapeutic approach. We aimed to evaluate if anti-hypertensive drugs enalapril, losartan or olmesartan have effects on monocyte miR profile in essential hypertensives without target organ involvement. For this purpose, 82 hypertensives and 49 controls were included; we evaluated SBP/DBP, lipid profile, glucose, CRP, fibrinogen, arterial stiffness indices (PWV; AIx), and cIMT at baseline (T0) and after 24 weeks of treatment (T1). Subjects with LDL-C ≥ 160 mg/dL, TG ≥ 200 mg/dL, BMI ≥ 30, and other additional CV risk factors were excluded. Patients who were prescribed to receive once-a-day enalapril 20 mg, losartan 100 mg or olmesartan 20 mg were eligible for the study. At T1, we found a significant improvement of SBP (−18.5%), DBP (−18%), HDL-C and LDL-C (+3% and −5.42%), glucose (−2.15%), BMI (−3.23%), fibrinogen (−11%), CRP (−17.5%,), AIx (−49.1%) PWV (−32.2%), and monocyte miR expression (miR-221: −28.4%; miR-222: −36%; miR-145: +41.7%) with respect to baseline. miR profile was compared to control subjects at baseline and at T1. We found some little difference in the behaviour of the three treatments on some variables: olmesartan was the most effective in reducing fibrinogen, DBP, CRP, and AIx (−13.1%, −19.3%, −21.4%, and −56.8%, respectively). Enalapril was the drug more significantly increasing the expression of miR-145. In conclusion, enalapril, losartan and olmesartan are effective in improving mechanical and humoral factors associated to AS and atherogenesis. These drugs appear to be able to modify miRs 221/222 and miR-145 expression in drug-naïve hypertensives, making it closer to that of control subjects; additionally, this provides a good blood pressure compensation, contributing to slow the progression of vascular damage. MDPI 2021-07-22 /pmc/articles/PMC8389596/ /pubmed/34440064 http://dx.doi.org/10.3390/biomedicines9080860 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mandraffino, Giuseppe
Lo Gullo, Alberto
Cinquegrani, Maria
D’Ascola, Angela
Sinicropi, Davide
Imbalzano, Egidio
Blando, Giuseppe
Campo, Giuseppe Maurizio
Morace, Carmela
Giuffrida, Clemente
Campo, Salvatore
Squadrito, Giovanni
Scuruchi, Michele
Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
title Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
title_full Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
title_fullStr Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
title_full_unstemmed Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
title_short Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
title_sort expression and change of mirs 145, 221 and 222 in hypertensive subjects treated with enalapril, losartan or olmesartan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389596/
https://www.ncbi.nlm.nih.gov/pubmed/34440064
http://dx.doi.org/10.3390/biomedicines9080860
work_keys_str_mv AT mandraffinogiuseppe expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT logulloalberto expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT cinquegranimaria expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT dascolaangela expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT sinicropidavide expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT imbalzanoegidio expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT blandogiuseppe expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT campogiuseppemaurizio expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT moracecarmela expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT giuffridaclemente expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT camposalvatore expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT squadritogiovanni expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan
AT scuruchimichele expressionandchangeofmirs145221and222inhypertensivesubjectstreatedwithenalaprillosartanorolmesartan